Moderna gets $590M from US government

Before beginning the discussion of where this company is going, let's set expectations appropriately. Moderna won't be ...
Eva Ados, ERshares COO and chief investment strategist, joins CNBC's 'Power Lunch' to share outlooks on three stocks.
The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...
While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...
The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...
RNA vaccine developer Moderna (MRNA) is climbing nearly 5% in early trading today after it was awarded about $590 million by ...